2126 — JW (Cayman) Therapeutics Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.11bn
- HK$830.20m
- CNY283.65m
Annual balance sheet for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1,834 | 1,383 | 1,006 | 757 | 503 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.86 | 29.4 | 0 | — | 2.23 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,895 | 1,485 | 1,067 | 809 | 570 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 381 | 394 | 343 | 276 | 211 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,117 | 2,791 | 2,146 | 1,680 | 987 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 199 | 311 | 264 | 465 | 394 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 326 | 437 | 462 | 511 | 431 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 2,791 | 2,354 | 1,684 | 1,169 | 556 |
| Total Liabilities & Shareholders' Equity | 3,117 | 2,791 | 2,146 | 1,680 | 987 |
| Total Common Shares Outstanding |